This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

LogicBio Therapeutics Dividende

Dividende contrôle des critères 0/6

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	1.9%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$0.81
Prévision de rendement du dividende	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Aug 20

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 18

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Jan 15

LogicBio extends collaboration with Children's Medical Research Institute

Jan 07

LogicBio Therapeutics names new CFO

Dec 22

Looking In On LogicBio

Nov 17

LogicBio reports Q3 results

Nov 09

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if LOGC's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if LOGC's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

LogicBio Therapeutics Rendement des dividendes par rapport au marché

Comment le rendement du dividende de LOGC se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (LOGC)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.3%
Moyenne du secteur (Biotechs)	1.9%
Analyste prévisionnel (LOGC) (jusqu'à 3 ans)	n/a

Dividende notable: Unable to evaluate LOGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate LOGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as LOGC has not reported any payouts.

This company has been acquired

LogicBio Therapeutics Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from NASDAQ Composite Index

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

LogicBio Therapeutics, Inc Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

Nasdaq Determines to Delist Securities of LogicBio Therapeutics

LogicBio Therapeutics, Inc. Announces Executive Changes

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

Price target decreased to US$3.00

Price target increased to US$7.67

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

LogicBio Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$6.50

No longer forecast to breakeven

Price target decreased to US$6.50

No longer forecast to breakeven

LogicBio Therapeutics, Inc Provides Update on LB-001 Clinical Development Program

Price target decreased to US$12.20

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

LogicBio Therapeutics, Inc. Provides Updates Around Its Sunrise Phase 1/2 Clinical Trial and Development Pipeline

Price target decreased to US$15.40

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.34 loss in 3Q 2020)

High number of new directors

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to US$18.80

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.35 loss in 2Q 2020)

LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from Russell 3000E Index

LogicBio Therapeutics Announces First Patient Dosed and Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.41 loss in 1Q 2020)

LogicBio EPS misses by $0.06, beats on revenue

Consensus revenue estimates increase to US$4.53m

LogicBio Therapeutics, Inc. Announces Clinical and Corporate Updates

LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

Price target lowered to US$20.25

New 90-day high: US$9.16

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

LogicBio extends collaboration with Children's Medical Research Institute

LogicBio Therapeutics, Inc. Announces Executives Changes, Effective January 11, 2021

LogicBio Therapeutics names new CFO

Logicbio Therapeutics Announces Executive Changes

LogicBio Therapeutics, Inc. Announces Board Changes

Looking In On LogicBio

LogicBio reports Q3 results

Logicbio Therapeutics, Inc. Announces to Receives FDA Fast Track Designation for Lb-001 for the Treatment of Methylmalonic Acidemia (Mma)

LogicBio Therapeutics, Inc. Announces Executive Changes

New 90-day low: US$5.29

LogicBio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $42 million.

New 90-day low: US$5.41

New 90-day low - US$6.58

New 90-day high - US$9.05

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés